KIMS Q1FY27: consolidated PAT down 56% YoY on expansion costs, revenue up 35%

Krishna Institute of Medical Sciences (KIMS) posted consolidated Q1 FY27 (quarter ended 30 June 2026) revenue of ₹1,179.5 Cr, up 35.3% YoY (₹871.6 Cr) and 9.8% QoQ (₹1,074.6 Cr), but consolidated PAT of ₹37.4 Cr fell 56.0% YoY (₹85.0 Cr) even as it rose 13.0% QoQ (₹33.1 Cr). Neither this quarter nor the year-ago quarter carried exceptional items, so the YoY decline is entirely operational, not a base-effect from one-offs. No formal street consensus for the quarter could be located in available previews; the commentary going into the print flagged FY27 as the year operating leverage was expected to start converting revenue growth into PAT expansion — this quarter runs counter to that framing on a YoY basis, so vsStreet is marked unknown rather than guessed. Consolidated NPM compressed to 3.2% from 9.7% a year ago (roughly flat versus 3.1% last quarter), and EBITDA margin eased to an estimated ~18.9% from ~22.1% a year ago. The squeeze traces to two lines below EBITDA: finance costs more than doubled YoY to ₹83.4 Cr (from ₹32.6 Cr) and depreciation rose 88.8% to ₹100.8 Cr (from ₹53.4 Cr), both reflecting the debt- and capex-funded capacity build-out. Three newly consolidated subsidiaries under ramp-up contributed combined revenue of ₹40.3 Cr but a net loss of ₹4.6 Cr for the quarter, directly matching management's Q4 guidance that near-term EBITDA margins would be hit by initial losses from new facilities. Tellingly, standalone (parent-only) PAT grew 13.1% YoY to ₹66.5 Cr on revenue of ₹483.6 Cr (+29.5% YoY) — the wide swing between standalone and consolidated growth confirms the drag sits with the newer Group subsidiaries and their financing, not the core hospital business. On guidance, the quarter reads as on-track rather than a miss: management had flagged margin pressure from new-unit ramp-up and a plan to bring net debt/EBITDA to 1:2 (from over ₹3,000 Cr of debt) via a QIP. The company closed that QIP during the quarter, issuing 1.987 Cr shares at ₹755 to raise ₹1,500 Cr, with proceeds still largely parked in mutual funds as of 30 June per the filing notes — which explains why finance costs had not yet eased. Shareholders separately cleared, at a 9 July EGM, up to ₹600 Cr of convertible warrants to promoters for further deleveraging headroom. The Board also approved loans/guarantees of up to ₹650 Cr to group entities and a draft O&M and Call Option agreement with Golden Lan Solutions and Sarwottam Healthcare (execution pending); separately, the Group completed one hospital O&M agreement this quarter, accounted for as a business combination under Ind AS 103. No standalone press-release commentary was available in the filing beyond these operational notes. Going into Q2 FY27, the markers to watch are whether finance costs start declining as QIP proceeds are deployed toward debt paydown, whether the loss-making new subsidiaries (₹4.6 Cr loss on ₹40.3 Cr revenue this quarter) narrow toward the 12-18 month EBITDA-breakeven management guided for new units, and whether consolidated NPM begins recovering off its current 3.2% base.